Novo Nordisk Inc.

Plainsboro, NJ ManufacturingNAICS 325410

Self-funded health planPlan year 2025Renews January
10,693Participants+23% vs. prior year
$25.4MEst. pharmacy spend / yrParticipants × national avg.
Jan 2027Next renewalPlan year begins January 1
#5 of 76Manufacturing in NJBy participants

Overview

Novo Nordisk Inc. sponsors a self-funded health plan that covered 10,693 participants in plan year 2025, up 23% from the prior year. The plan year starts in January. Alongside medical, its benefits filing reports life insurance, dental, vision, short-term disability, and more.

Plan type
ERISA welfare benefit plan, self-funded (benefits paid from employer assets or a trust)
Participants
10,693 · prior year 8,730
Plan year
Begins January 1 · next renewal January 2027
Health plans filed
Novo Nordisk Inc. Welfare Benefit Plan, plan 501 (10,693 participants); Novo Nordisk Inc. 2012 Retiree Health Plan, plan 601 (399 participants)
Broker compensation
$190K across insured contracts
MedicalLife insuranceDentalVisionShort-term disabilityLong-term disabilitySeveranceDeath benefitsOther welfare benefits

Insurance carriers

Insured coverage reported on Schedule A. Self-funded medical claims aren't reported there.

CarrierCoverageCoveredPremiumBroker comp
Lincoln National Life Insurance CompanyLong-term disability, Life10,693$12.6M$190K
Eyemed Vision Care on Behalf of Fidelity Security Life Insurance Co.Vision21,706$1.7M—
UnitedHealthcare Insurance CompanyMedicare Supplement, Prescription drug391$1.3M—
Magellan HealthEmployee Assistance Program7,967$287K—
Aetna Life Insurance Co.Dental821$182K—
Ace American Insurance CompanyBusiness Travel Accident10,693$88K—

Pharmacy benefit estimate

StreamRX estimate for a plan this size. Not based on this plan's claims.

$25.4M/ year

Estimated prescription spend: 10,693 participants × $2,371 national average per member. Usually higher once dependents are counted.

$659K–$1.6M/ year

Typical savings opportunity found in independent reviews of plans this size.

Brands with a generic available$193K–$482K
Lower-cost therapeutic alternatives$281K–$588K
Generic pricing vs. actual cost$122K–$365K
PBM contract terms$63K–$190K
The DOL's PBM fee disclosure rule first applies to this plan for the plan year beginning January 2028: semiannual PBM compensation reports and an annual audit right.

Form 5500 filing details

Filing
Form 5500 with Schedule A, plan year 2025
Plan sponsor
Novo Nordisk Inc.
Sponsor EIN
06-1061602
Plan numbers
501, 601
Filed with
U.S. Department of Labor (EBSA) via EFAST2

Verify this filing: search EIN 06-1061602 in the Department of Labor's EFAST2 Form 5500 search.

Retirement plan

Plan
Novo Nordisk Inc. 401(k) Savings Plan
Type
401(k) plan
Participants
13,805

About this data

Source: Novo Nordisk Inc.'s Form 5500 filing for plan year 2025 and its Schedule A insurance reports, published by the U.S. Department of Labor. "Self-funded" means the filing reports benefits paid from employer assets or a trust, with no medical insurance contract or with a stop-loss contract. Pharmacy figures are StreamRX estimates based on national averages. StreamRX is not affiliated with Novo Nordisk Inc..

Request a correction · Methodology